Delivery Order SPE2DB22D1017-SPE2DB25FG3XV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,918.20 to AmerisourceBergen Drug Corp for the supply of Trumenba 120 micrograms/0.5 milliliter vaccine in 0.5-milliliter doses. This firm fixed-price delivery order was competitively awarded with no set-aside designation and has an ultimate completion date of January 6, 2026. The vaccine will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office. This delivery order is...
- The Defense Logistics Agency awarded a $1,062.52 firm fixed price delivery order to AmerisourceBergen Drug Corp for Trumenba 120 MCG/0.5 ML vaccine on August 19, 2025, with completion targeted for August 20, 2025. This non-set-aside award represents a single delivery order under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, which serves as the performance site for this pharmaceutical...
- The Defense Logistics Agency awarded a $2,125.04 delivery order to AmerisourceBergen Drug Corp for Trumenba 120 MCG/0.5 ML vaccine on September 19, 2025, with an ultimate completion date of September 22, 2025. This competitively awarded, firm fixed-price contract is classified as a delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,872.68 to AmerisourceBergen Drug Corp for the supply of Trumenba 120 mcg/0.5 ml vaccine in 0.5 ml units. This non-set-aside, firm fixed-price delivery order was awarded on September 8, 2025, with an ultimate completion date of September 9, 2025. Performance will take place at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a procurement of pharmaceutical products supporting the federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Trumenba 120 micrograms/0.5 milliliter vaccine in 0.5 milliliter units, with a ceiling value of $1,749.30 and firm fixed pricing. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The performance location is...
- This delivery order, valued at $1,264.96, was awarded to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Trumenba 120 MCG/0.5 ML vaccine in 0.5 ML quantities. The contract is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA), with performance to be completed by April 25, 2025, and fulfillment at the vendor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement, indicating it was...
- The Defense Logistics Agency awarded a delivery order valued at $1,062.52 to AmerisourceBergen Drug Corp for the supply of Trumenba (meningococcal vaccine B) 120 mcg/0.5 mL doses on August 14, 2025, with completion targeted for August 15, 2025. The order represents a firm fixed price, competitively awarded delivery against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,062.52 contract is for the supply of 120 mcg/0.5 ml doses of the Trumenba vaccine, with a performance period ending on May 8, 2025. The award is not set-aside and represents an open competition. AmerisourceBergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,125.04 for TRUMENBA 120MCG (meningococcal B vaccine) on July 28, 2025, with an ultimate completion date of July 29, 2025. The contract, which was competitively awarded with no set-aside designation, utilizes firm fixed pricing and is being performed at the company's Conshohocken, PA facility. This delivery order falls under the Defense Logistics...
- This federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division is for the provision of Trumenba 120 mcg/0.5 ml vaccine in 0.5 ml doses. The firm-fixed-price delivery order has a ceiling value of $2,887.80 and an ultimate completion date of June 14, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a single-award Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued up to $999,999,999.00...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG3XVDelivery Order
The Defense Logistics Agency (DLA) awarded a $1,097.44 delivery order to AmerisourceBergen Drug Corp for the supply of Trumenba 120 mcg/0.5 ml vaccine in 0.5 ml units. The contract was competitively awarded without set-aside provisions and carries a firm fixed price. The award was executed on June 2, 2025, with an ultimate completion date of June 3, 2025, and performance will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, has established itself as a critical vendor for federal medical procurement through its extensive portfolio of pharmaceutical products and medical supplies. The company's federal contract awards consistently demonstrate capability to meet military healthcare requirements across multiple therapeutic domains, including vaccines, specialty medications, and medical supplies, with delivery orders employing firm fixed pricing models. This particular vaccine delivery order represents one transaction within the broader pharmaceutical prime vendor framework that supports U.S. military and federal health systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 6/2/25 |